Title: A Single arm, open label, phase II trial of alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling.
The aim of this ASPiRATION and MoST substudy to assess the clinical activity of of alectinib in adult patients with advanced cancers harbouring an ALK gene alteration.
Adult patients with advanced cancers harbouring ALK gene alterations identified using CGP. NSCLC patients with ALK gene alterations must be FISH-negative, i.e. not eligible for reimbursed ALK-targeted treatment.